1-2 of 2
Gopi Madhav Bommidi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Treatment cost per AE symptom-free day of asciminib and second-generation tyrosine kinase inhibitors in newly diagnosed patients with chronic myeloid leukemia

Free
Jennifer Vaughn, Nadine Zawadzki, Caroline Hardy, Gabriel Marquez, Gopi Madhav Bommidi, Poornima Sachin Dhobe, Sai Vasmi Gedala, Islam Mohamad Sadek, Jason Shafrin, David Wei
Journal: Blood
Blood (2025) 146 (Supplement 1): 2835.
https://doi.org/10.1182/blood-2025-2835
Published: 2025
Journal Articles

Improved long-term tolerability with asciminib (ASC) vs investigator-selected (IS) tyrosine kinase inhibitors (TKIs) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Week 96 exploratory analysis of the phase 3 ASC4FIRST trial

Free
Timothy Hughes, Jorge Cortes, Jennifer Vaughn, Kathryn Flynn, Naoto Takahashi, Ghayas Issa, Felice Bombaci, Jianxiang Wang, Dong-Wook Kim, Dennis Kim, Jiri Mayer, Yeow Tee Goh, Philipp le Coutre, Inho Kim, Gabriel Etienne, Rajendra Jinwal, Andrea Damon, David Wei, Gabriel Marquez, Ennan Gu, Gopi Madhav Bommidi, Andreas Hochhaus, Richard Larson
Journal: Blood
Blood (2025) 146 (Supplement 1): 5549.
https://doi.org/10.1182/blood-2025-5549
Published: 2025